Nanomedicine (London, England)最新文献_第6页

Results of phase Ib/II trial of PEP503 (NBTXR3, radioenhancer) with chemoradiotherapy in patients with rectal cancer. PEP503 （NBTXR3，放射线增强剂）与直肠癌患者放化疗的Ib/II期试验结果。

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-04-21 DOI: 10.1080/17435889.2025.2487411

Ching-Wen Huang, Huang-Ming Hu, Wen-Hung Hsu, Chiao-Yun Chen, Ming-Yii Huang, Chou-Pin Chen, Po-Li Wei, Bor-Nian Shen, Tsung-Kun Chang, Jaw-Yuan Wang

{"title":"Results of phase Ib/II trial of PEP503 (NBTXR3, radioenhancer) with chemoradiotherapy in patients with rectal cancer.","authors":"Ching-Wen Huang, Huang-Ming Hu, Wen-Hung Hsu, Chiao-Yun Chen, Ming-Yii Huang, Chou-Pin Chen, Po-Li Wei, Bor-Nian Shen, Tsung-Kun Chang, Jaw-Yuan Wang","doi":"10.1080/17435889.2025.2487411","DOIUrl":"https://doi.org/10.1080/17435889.2025.2487411","url":null,"abstract":"Aim: To evaluate the efficacy, recommended phase II dose (RP2D), dose-limiting toxicity (DLT), and safety profiles of PEP503 (NBTXR3) in combination with concurrent chemoradiotherapy (CCRT) in patients with locally advanced or unresectable rectal adenocarcinoma.Methods: A single administration of intratumor injection of PEP503 (NBTXR3) (multiple punctures) was applied, followed by radiotherapy in combination with capecitabine or 5-fluorouacil (5-FU). Surgery was performed 8 to 12 weeks after completion of CCRT.Results: Thirty-two patients were enrolled (one dropped out before CCRT), comprising 20 in phase Ib and 12 in phase II. The disease control rate was 100% (n = 31). One (3.2%) and 19 (61.3%) patients achieved clinical complete response and partial response, respectively. Twenty-five patients underwent surgery, of whom 24 (96%) had R0 resection and 5 (20%) had pathological complete response. Most of the adverse events were grade 1/2 events.Conclusion: Intratumor injection of PEP503 (NBTXR3) in patients with locally advanced or unresectable rectal adenocarcinoma is safe and effective. Addition of PEP503 (NBTXR3) to fluoropyrimidine-based neoadjuvant CCRT does not engender increased toxicity. The strong safety profile and encouraging efficacy of PEP503 (NBTXR3) in combination with neoadjuvant CCRT in locally advanced or unresectable rectal cancer warrant further examination in clinical studies.Clinical trial registration: This study was registered on ClinicalTrials.gov Identifier: NCT02465593.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":"20 9","pages":"929-941"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How can membrane lipid constituency be manipulated to produce liposomes with desired functions? 如何操纵膜脂成分以产生具有所需功能的脂质体？

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-02-24 DOI: 10.1080/17435889.2025.2469485

T Issler, S Lisowski, K Farzi, E J Prenner

引用次数: 0

Realizing the potential of nanomedicines to treat breast cancer liver metastasis. 实现纳米药物治疗乳腺癌肝转移的潜力。

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-02-27 DOI: 10.1080/17435889.2025.2469491

Biana Godin, Hermann B Frieboes

引用次数: 0

Wheat germ agglutinin-nanoparticles encapsulating itacitinib target and suppress pro-inflammatory slan+ monocytes. 包裹伊他替尼的小麦胚芽凝集素纳米颗粒靶向并抑制促炎的slan+单核细胞。

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-04-28 DOI: 10.1080/17435889.2025.2494500

Karen Alvarez, Cristian A Anacona, Esneyder Ruiz Agudelo, Paula Losada, Víctor H Orozco, Luis Fernando Giraldo, Gloria Vásquez, Daniel Rodriguez, Juan Camilo Díaz, Ricardo Pineda, Mauricio Rojas

{"title":"Wheat germ agglutinin-nanoparticles encapsulating itacitinib target and suppress pro-inflammatory slan+ monocytes.","authors":"Karen Alvarez, Cristian A Anacona, Esneyder Ruiz Agudelo, Paula Losada, Víctor H Orozco, Luis Fernando Giraldo, Gloria Vásquez, Daniel Rodriguez, Juan Camilo Díaz, Ricardo Pineda, Mauricio Rojas","doi":"10.1080/17435889.2025.2494500","DOIUrl":"https://doi.org/10.1080/17435889.2025.2494500","url":null,"abstract":"Background: 6-sulfoLacNAc (slan)+ monocytes, a non-classical monocyte subset, play a pro-inflammatory role in autoimmune diseases like systemic lupus erythematosus (SLE). This study evaluates the therapeutic potential of itacitinib (ITA) encapsulated in wheat germ agglutinin-functionalized nanoparticles (WGA/F127/PNPs) to target and inhibit the JAK-STAT pathway in slan+ monocytes.Methods: We prepared ITA-loaded WGA/F127/PNPs and analyzed their binding and internalization in various leukocyte subsets using flow cytometry, focusing on slan+ and slan- monocytes. Further, peripheral blood samples from healthy controls (n = 37) and SLE patients (n = 50) were used to assess slan+ monocyte phenotypes. Co-cultures of slan+ and slan- monocytes stimulated with LPS revealed that slan+ monocytes significantly increased HLA-DR expression.Results: Results showed that slan+ monocytes from SLE patients were reduced compared to healthy controls (p < 0.001) and that slan+ monocytes effectively internalized WGA/F127/PNPs, unlike slan- cells. ITA-loaded nanoparticles decreased HLA-DR, CD69, and CD86 expression, STAT1 phosphorylation, and cytokine production in IFN-γ-stimulated slan+ monocytes. Findings support WGA/F127/PNPs as a promising drug delivery system for targeting slan+ monocytes, providing new therapeutic potential for SLE.Conclusion: ITA-loaded WGA/F127/PNPs effectively target and suppress pro-inflammatory slan+ monocytes, presenting a promising, cell-specific therapeutic approach for managing systemic lupus erythematosus and related autoimmune disorders.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":"20 10","pages":"1113-1126"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144030714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synergistic approach of PEGylated photothermal agent and immunomodulator in cancer immunotherapy. 聚乙二醇化光热剂与免疫调节剂在肿瘤免疫治疗中的协同作用。

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-04-11 DOI: 10.1080/17435889.2025.2489342

Gong Yi Yong, Anyanee Kamkaew, Chin Siang Kue

引用次数: 0

PLGA nanoparticle-mediated anti-inflammatory gene delivery for the treatment of neuropathic pain. PLGA纳米颗粒介导的抗炎基因传递治疗神经性疼痛。

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-04-05 DOI: 10.1080/17435889.2025.2487410

Boomin Choi, Subeen Lee, Seohyun Chung, Ellane Eda Barcelona, Jinpyo Hong, Sung Joong Lee

{"title":"PLGA nanoparticle-mediated anti-inflammatory gene delivery for the treatment of neuropathic pain.","authors":"Boomin Choi, Subeen Lee, Seohyun Chung, Ellane Eda Barcelona, Jinpyo Hong, Sung Joong Lee","doi":"10.1080/17435889.2025.2487410","DOIUrl":"10.1080/17435889.2025.2487410","url":null,"abstract":"Aim: This study aimed to mitigate neuropathic pain behavior in a sciatic nerve transection (SNT)-induced mouse model by delivering anti-inflammatory cytokines - interleukin-4 (IL-4), interleukin-10 (IL-10), and transforming growth factor-beta 1 (TGF-β1) - via poly(d,l-lactic-co-glycolic acid) (PLGA) nanoparticles (NPs).Materials & methods: Upon gene delivery of IL-4, IL-10, and TGF- β1, the anti-inflammatory effects and induction of microglia M2 polarization were evaluated. Plasmid (IL-4, IL-10, and TGF-β1)-encapsulated PLGA NPs (PLGA@IL-4, PLGA@IL-10, and PLGA@TGF-β1) were synthesized and characterized for size, zeta potential, cellular toxicity, and cellular uptake. The analgesic effect of anti-inflammatory gene delivery using PLGA NPs was then assessed in a mouse model of neuropathic pain.Results: Gene delivery of IL-4, IL-10, and TGF-β1 showed a significant anti-inflammatory effect in LPS-treated cells and IL-4 strongly promoted microglia M2 polarization in vitro. PLGA NPs successfully delivered the anti-inflammatory cytokine-coding genes into mouse spinal cord cells, specifically targeting microglia. PLGA@IL-4, PLGA@IL-10, and PLGA@TGF-β1 NPs produced analgesic effects in a SNT-induced mouse neuropathic pain model. Notably, PLGA@IL-4 demonstrated the most effective and remarkably long-lasting analgesic effect, strongly enhancing microglia M2 polarization in spinal cord microglia.Conclusion: Gene therapy using PLGA NPs for overexpression of anti-inflammatory cytokines could be a promising strategy for the treatment of neuropathic pain.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"943-954"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent strategies for enhanced delivery of mRNA to the lungs. 增强mRNA向肺部传递的最新策略。

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-04-07 DOI: 10.1080/17435889.2025.2485669

Brittany J Heiser, Arian Veyssi, Debadyuti Ghosh

{"title":"Recent strategies for enhanced delivery of mRNA to the lungs.","authors":"Brittany J Heiser, Arian Veyssi, Debadyuti Ghosh","doi":"10.1080/17435889.2025.2485669","DOIUrl":"10.1080/17435889.2025.2485669","url":null,"abstract":"mRNA-based therapies have emerged as a transformative tool in modern medicine, gaining significant attention following their successful use in COVID-19 vaccines. Delivery to the lungs offers several compelling advantages for mRNA delivery. The lungs are one of the most vascularized organs in the body, which provides an extensive surface area that can facilitate efficient drug transport. Local delivery to the lungs bypasses gastrointestinal degradation, potentially enhancing therapeutic efficacy. In addition, the extensive capillary network of the lungs provides an ideal target for systemic delivery. However, developing effective mRNA therapies for the lungs presents significant challenges. The complex anatomy of the lungs and the body's immune response to foreign particles create barriers to delivery. This review discusses key approaches for overcoming these challenges and improving mRNA delivery to the lungs. It examines both local and systemic delivery strategies aimed at improving lung delivery while mitigating off-target effects. Although substantial progress has been made in lung-targeted mRNA therapies, challenges remain in optimizing cellular uptake and achieving therapeutic efficacy within pulmonary tissues. The continued refinement of delivery strategies that enhance lung-specific targeting while minimizing degradation is critical for the clinical success of mRNA-based pulmonary therapies.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1043-1069"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143797356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanomaterials as electromagnetic sensors for tumour detection. 纳米材料作为肿瘤检测的电磁传感器。

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-05-02 DOI: 10.1080/17435889.2025.2496130

Annah J Wilson, Paul B Cressey, Navid Ghavami, Sadie Carter-Searjeant, Mark Green, Panagiotis Kosmas, Maya Thanou

{"title":"Nanomaterials as electromagnetic sensors for tumour detection.","authors":"Annah J Wilson, Paul B Cressey, Navid Ghavami, Sadie Carter-Searjeant, Mark Green, Panagiotis Kosmas, Maya Thanou","doi":"10.1080/17435889.2025.2496130","DOIUrl":"https://doi.org/10.1080/17435889.2025.2496130","url":null,"abstract":"Aim: Microwave (MW) imaging/sensing is a potential clinical diagnostic technique which exploits differences in the dielectric properties of tissues at MW frequencies. Notably, breast cancer detection has been identified as a key application for this modality; however, inherent contrast in tissue dielectric properties may not always be sufficient to allow imaging/sensing. Nanoparticles could provide the necessary enhancement, due to their effect on the dielectric properties of the target tissue and their ability to accumulate in tumours. This study aims to prepare novel zinc ferrites ZnFe2O4 nanoparticles and investigate their potential as contrast agents for MW imaging/sensing.Method: Zinc ferrite nanoparticles were synthesized by thermal decomopositon and phase transferred using a co-polymer to improve biocompatibility. Dielectric properties were evaluated using the co-axial probe technique, progressing to ex vivo and in vivo studies in a triple-negative breast cancer xenograft mouse model.Results: Tumours regions injected subcutaneously with nanoparticles in vivo showed an increased dielectric constant of up to 49% compared with approximately 3% ex vivo. Significant increases in conductivity were also observed indicating potential application of the particles as MW hyperthermia sensitizers.Conclusions: Crucially, this study presents the first in vivo evaluation of nanoparticles as contrast agents for MW imaging/sensing. Observed increases in the dielectric properties highlight their potential to improve tumour detection using MW technologies.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":"20 10","pages":"1139-1148"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanomaterial-based approaches to neurotoxin neutralization in neurodegenerative diseases. 神经退行性疾病中基于纳米材料的神经毒素中和方法。

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-04-03 DOI: 10.1080/17435889.2025.2487409

Meng Cheng, Yan Dou

{"title":"Nanomaterial-based approaches to neurotoxin neutralization in neurodegenerative diseases.","authors":"Meng Cheng, Yan Dou","doi":"10.1080/17435889.2025.2487409","DOIUrl":"10.1080/17435889.2025.2487409","url":null,"abstract":"Neurodegenerative diseases (NDs) are intricately linked to the accumulation of various neurotoxins, mainly including toxic proteins, inflammatory mediators, excess metal ions, and viral pathogens. Biological neutralization strategies that use agents to competitively bind harmful substances and thus inhibit their pathogenic activity hold promise for direct removal of neurotoxins but face many limitations and challenges in NDs. Nanomaterials provide a potential solution for neurotoxin neutralization in NDs due to their unique physicochemical and biological properties. This review summarizes recent advancements in nanomaterial-based approaches to neurotoxin neutralization in NDs, highlighting the diverse design principles and mechanisms of action. We also discuss the critical role of targeted delivery to optimize neutralization efficiency and the advantages of combining different neutralization mechanisms or introducing other therapeutic components to exert the synergistic effects. Furthermore, we reveal current limitations and future research directions aimed at paving the way for nanomedicine development based on neurotoxin neutralization for the treatment of NDs.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1015-1027"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051574/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanotherapeutics induced redox resetting of oxidative and nitrosative stress: targeting glutathione-depletion in cancer. 纳米疗法诱导氧化应激和亚硝化应激的氧化还原重置：靶向癌症中的谷胱甘肽耗竭。

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-04-07 DOI: 10.1080/17435889.2025.2489918

Kapil Dangi, Vijay Kumar, Disha Mittal, Pooja Yadav, Mansi Malik, Anita Kamra Verma

{"title":"Nanotherapeutics induced redox resetting of oxidative and nitrosative stress: targeting glutathione-depletion in cancer.","authors":"Kapil Dangi, Vijay Kumar, Disha Mittal, Pooja Yadav, Mansi Malik, Anita Kamra Verma","doi":"10.1080/17435889.2025.2489918","DOIUrl":"10.1080/17435889.2025.2489918","url":null,"abstract":"Cancer cells display a distinctive defense mechanism against any exogenous moieties that renders all treatments inefficient. Glutathione, a thiol tripeptide plays a paradoxical role in cancer as intracellular glutathione (GSH) are voracious scavengers of free radicals produced by chemotherapy, generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS). Cancer cells show Warburg effect, wherein the intracellular GSH levels are exceptionally enhanced to overcome the oxidative stress created by ROS/RNS production or by the other free radicals generated as side products of intracellular redox reactions. Therefore, redox resetting is essential to maintain the redox homeostasis for cell survival and their proliferation and trigger escalation of GSH levels. Nanotherapeutics have facilitated the targeted delivery of GSH-depleting agents in combination with radiotherapy, chemotherapy, and novel therapeutic interventions including chemodynamic therapy (CDT), photodynamic therapy (PDT), ferroptosis induction, sonodynamic therapy (SDT), and immunotherapy are being explored. This review aims to compile the strategic role of GSH in cancer cells, the importance of nanotherapeutics for GSH depletion in cancer to target numerous forms of programmed cell death (PCD), including apoptosis, ferroptosis, necroptosis, and autophagy.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"955-965"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143797344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0